Q2 2026 · 13F-HR
Atle Fund Management ABholdings as filed
Filed 2026-07-24 · accession 0001381843-26-000005
$371.7M
Reported value
39
Positions
2026-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | ELI LILLY & CO | $35.8M | 9.62% | 29,821 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO. INC | $24.3M | 6.55% | 189,357 | Common | SOLE |
| 478160104 | JNJ | JOHNSON & JOHNSON | $21.7M | 5.84% | 85,425 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $16.2M | 4.35% | 64,325 | Common | SOLE |
| 126650100 | CVS | CVS HEALTH CORP | $15.1M | 4.07% | 146,102 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC CORP | $14.0M | 3.76% | 27,859 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $13.7M | 3.68% | 73,077 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $13.6M | 3.65% | 62,781 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $12.3M | 3.31% | 72,898 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $11.8M | 3.17% | 100,807 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $11.2M | 3.01% | 213,329 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $10.9M | 2.93% | 137,131 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD-ADR | $10.0M | 2.70% | 35,180 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $9.8M | 2.64% | 24,656 | Common | SOLE |
| 863667101 | SYK | STRYKER CORPORATION | $9.5M | 2.57% | 30,283 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $9.5M | 2.56% | 19,131 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $9.3M | 2.51% | 103,230 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $9.3M | 2.50% | 124,707 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH, INC | $8.9M | 2.40% | 24,019 | Common | SOLE |
| 03073E105 | COR | CENCORA INC | $8.8M | 2.37% | 31,126 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $8.4M | 2.27% | 248,848 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $7.8M | 2.09% | 58,170 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $6.5M | 1.74% | 56,953 | Common | SOLE |
| 450056106 | IRTC | IRHYTHM TECHNOLOGIES INC | $6.4M | 1.73% | 54,102 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFC | $6.2M | 1.68% | 146,381 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $6.2M | 1.67% | 58,378 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $6.2M | 1.67% | 198,557 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $5.8M | 1.57% | 46,142 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $5.6M | 1.51% | 23,630 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTI | $5.2M | 1.41% | 54,886 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $5.1M | 1.36% | 57,030 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $4.8M | 1.30% | 71,846 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $4.3M | 1.16% | 145,657 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $3.5M | 0.95% | 94,478 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $3.5M | 0.94% | 33,313 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $3.2M | 0.86% | 43,682 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $2.9M | 0.78% | 966,459 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $2.3M | 0.62% | 1,048,593 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES | $2.0M | 0.53% | 88,556 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.